Navigation Links
Indianapolis Residents View Economic Challenges as Significant Barrier to Properly Managing Type 2 Diabetes
Date:5/12/2009

Cost of diabetes treatments, local gyms and fresh food among barriers preventing Indianapolis residents from implementing healthy habits to take control of their diabetes

INDIANAPOLIS, May 12 /PRNewswire/ -- Taking Control of Your Diabetes (TCOYD), a not-for-profit organization dedicated to informing and empowering people with diabetes to become actively involved in their own health care, announced findings today from a recent survey conducted by national research firm Yankelovich which found that while Indianapolis residents with type 2 diabetes receive a significant amount of education on diabetes management, several factors, including economic constraints, are restricting them from translating this knowledge into actionable steps, which can lead to serious health risks.

The survey findings demonstrate an urgent need for motivational diabetes education. In fact, TCOYD will be holding a diabetes education conference on May 30, 2009, at the Indiana Convention Center, offering practical, hands-on advice and lifestyle recommendations, as well as educational workshops and resources, to empower residents to take an active role in proper diabetes management. In addition to extensive educational offerings, the conference also features hands-on physical activities like walking groups using pedometers and instruction on how to tone using resistance bands.

Eight out of 10 Indianapolis residents understand that excess body weight has a negative impact on their diabetes, and almost three in four have met with a diabetes educator or dietitian to receive more information on managing the disease. Despite this knowledge many residents struggle with taking the next step in implementing healthy eating and exercise habits into their daily lives. Almost three in four see their lack of willpower as a barrier to managing their diabetes and weight, citing not eating as healthy as they should and lack of exer
'/>"/>

SOURCE Taking Control of Your Diabetes
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Taking Control of Your Diabetes Conference Returns to Indianapolis to Bring Answers, Advocacy and Hope for People With Diabetes
2. Mind and Body Reunite as Premier Indianapolis Psychiatry Practice Adds Integrative Medicine
3. Former Mayor of Indianapolis to Serve as a Senior Strategic Advisor to McKenna Long & Aldridge LLPs Global Infrastructure Finance and Public-Private Partnerships Practice
4. SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay
5. Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 3 in Indianapolis
6. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Indianapolis is Participating
7. National Pharmaceutical Company to Sponsor Popular Indianapolis Walk
8. Publicis Indianapolis and St. Vincent Hospital Win the Gold
9. Skanska Opens Indianapolis Office
10. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
11. Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 1AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 1Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 3PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 1PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 2
Other Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10